Related Experiment Videos
[Tribulations of the p16/MTS1/CDKN2 tumor gene suppressor: a continuing saga]
1INSERM U. 301, Institut de génétique moléculairer, Paris, France.
Abstract:
Since its recent discovery on chromosome 9p21 band, the p16INK4a/MTS1/CDKN2 gene has been reported as one of the most frequently impaired tumor suppressor genes (ranking second after p53) in a variety of malignancies, including acute lymphoblastic leukemias. In fact, the situation is likely to be more complex than expected: the gene has a very unusual status in that sense that it encodes two structurally unrelated but functionally similar proteins, p16INK4a and p19ARF. In this minireview, the present status of the gene is examined.
Insights
The CDKN2 gene, a key tumor suppressor, encodes two distinct proteins, p16INK4a and p19ARF. This gene is frequently altered in various cancers, including leukemia.
Area of Science:
- Genetics
- Oncology
- Molecular Biology
Context:
- The CDKN2 gene, located on chromosome 9p21, is a critical tumor suppressor gene.
- It is frequently impaired in numerous malignancies, ranking second only to the p53 gene.
- Its significance is highlighted in conditions such as acute lymphoblastic leukemias.
Purpose:
- To review the current understanding of the CDKN2 gene.
- To explore the complex nature of this gene's function and implications in cancer.
Summary:
- The CDKN2 gene has a unique characteristic of encoding two structurally different yet functionally similar proteins: p16INK4a and p19ARF.
- This dual protein expression adds complexity to its role as a tumor suppressor.
- The review examines the current status and implications of these findings.
Impact:
- Understanding the dual protein products of CDKN2 can lead to more targeted cancer therapies.
- Further research into CDKN2 alterations may reveal new diagnostic or prognostic markers.
- This knowledge is crucial for advancing cancer research and treatment strategies.